Literature DB >> 10606239

Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

M Brangi1, T Litman, M Ciotti, K Nishiyama, G Kohlhagen, C Takimoto, R Robey, Y Pommier, T Fojo, S E Bates.   

Abstract

The mitoxantrone resistance (MXR) gene encodes a recently characterized ATP-binding cassette half-transporter that confers multidrug resistance. We studied resistance to the camptothecins in two sublines expressing high levels of MXR: S1-M1-80 cells derived from parental S1 colon cancer cells and MCF-7 AdVp3,000 isolated from parental MCF-7 breast cancer cells. Both cell lines were 400- to 1,000-fold more resistant to topotecan, 9-amino-20(S)-camptothecin, and the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), than their parental cell lines. The cell lines demonstrated much less resistance to camptothecin and to several camptothecin analogues. Reduced accumulation and energy-dependent efflux of topotecan was demonstrated by confocal microscopy. A significant reduction in cleavable complexes in the resistant cells could be observed after SN-38 treatment but not after camptothecin treatment. In addition to topotecan and SN-38, MXR-overexpressing cells are highly resistant to mitoxantrone and epirubicin. Because these compounds are susceptible to glucuronidation, we examined UDP-glucurono-syltransferase (UGT) activity in parental and resistant cells by TLC. Glucuronides were found at equal levels in both parental and resistant colon cancer cell lines for epirubicin and to a lesser extent for SN-38 and mitoxantrone. Low levels of glucuronidation could also be detected in the resistant breast cancer cells. These results were confirmed by analysis of the UGT1A family mRNAs. We thus conclude that colon and breast cancer cells have a capacity for glucuronidation that could contribute to intrinsic drug resistance in colon cancer cells and may be acquired in breast cancer cells. The lack of selection for higher levels of UGT capacity in the colon cells suggests that high levels of expression of MXR alone are sufficient to confer resistance to the camptothecins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10606239

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

Authors:  Dhriti Sooryakumar; Thomas S Dexheimer; Beverly A Teicher; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2011-06-02       Impact factor: 6.261

Review 2.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

3.  Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo.

Authors:  Sheng Zhou; John J Morris; Yuxiao Barnes; Lubin Lan; John D Schuetz; Brian P Sorrentino
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

4.  Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.

Authors:  Jhanelle Gray; Christopher L Cubitt; Shumin Zhang; Alberto Chiappori
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

5.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

Review 6.  Targeting Topoisomerase I in the Era of Precision Medicine.

Authors:  Anish Thomas; Yves Pommier
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

Review 7.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

8.  Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

Authors:  Julian R Molina; Scott H Kaufmann; Joel M Reid; Stephen D Rubin; Marina Gálvez-Peralta; Robert Friedman; Karen S Flatten; Kevin M Koch; Tona M Gilmer; Robert J Mullin; Roxanne C Jewell; Sara J Felten; Sumithra Mandrekar; Alex A Adjei; Charles Erlichman
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

9.  Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

Authors:  Zhiyong Liao; Robert W Robey; Josée Guirouilh-Barbat; Kenneth K W To; Orsolya Polgar; Susan E Bates; Yves Pommier
Journal:  Mol Pharmacol       Date:  2007-11-05       Impact factor: 4.436

Review 10.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.